Caseware UK (AP4) 2023.0.135 2023.0.135 2024-12-312024-12-312025-05-07The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.true2023-08-08falseResearch and experimental development on biotechnology170false 15057199 2023-08-07 15057199 2023-08-08 2024-12-31 15057199 2022-08-08 2023-08-07 15057199 2024-12-31 15057199 c:Director1 2023-08-08 2024-12-31 15057199 d:ComputerEquipment 2023-08-08 2024-12-31 15057199 d:ComputerEquipment 2024-12-31 15057199 d:ComputerEquipment d:OwnedOrFreeholdAssets 2023-08-08 2024-12-31 15057199 d:CurrentFinancialInstruments 2024-12-31 15057199 d:CurrentFinancialInstruments d:WithinOneYear 2024-12-31 15057199 d:ShareCapital 2024-12-31 15057199 d:RetainedEarningsAccumulatedLosses 2024-12-31 15057199 d:AcceleratedTaxDepreciationDeferredTax 2024-12-31 15057199 c:OrdinaryShareClass1 2023-08-08 2024-12-31 15057199 c:OrdinaryShareClass1 2024-12-31 15057199 c:FRS102 2023-08-08 2024-12-31 15057199 c:AuditExempt-NoAccountantsReport 2023-08-08 2024-12-31 15057199 c:FullAccounts 2023-08-08 2024-12-31 15057199 c:PrivateLimitedCompanyLtd 2023-08-08 2024-12-31 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 15057199









AAVANTGARDE BIO UK LIMITED







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE 17 MONTH PERIOD ENDED 31 DECEMBER 2024

 
AAVANTGARDE BIO UK LIMITED
REGISTERED NUMBER: 15057199

STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2024

2024
Note
£

Fixed assets
  

Tangible assets
 4 
51,458

  
51,458

Current assets
  

Trade and other receivables
 5 
4,123,348

Cash at bank and in hand
 6 
236,635

  
4,359,983

Current liabilities
  

Trade and other payables
 7 
(4,105,722)

Net current assets
  
 
 
254,261

Total assets less current liabilities
  
305,719

Provisions for liabilities
  

Deferred tax
  
(6,732)

  
 
 
(6,732)

Net assets
  
298,987


Capital and reserves
  

Share capital
 9 
-

Retained earnings
  
298,987

Total equity
  
298,987


Page 1

 
AAVANTGARDE BIO UK LIMITED
REGISTERED NUMBER: 15057199
    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 DECEMBER 2024

The Director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the 17 month period in question in accordance with section 476 of the Companies Act 2006.

The Director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The Company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 



Natalia Misciattelli
Director

Date: 7 May 2025

The notes on pages 3 to 10 form part of these financial statements.

Page 2

 
AAVANTGARDE BIO UK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE 17 MONTH PERIOD ENDED 31 DECEMBER 2024

1.


General information

Aavantgarde Bio UK Limited (the "Company") is a private company limited by shares and is incorporated, domiciled and registered in England and Wales (Registered number: 15057199). The nature of the Company’s operations is set out in the Directors' Report on page 1. The address of its registered office is Thomas House, 84 Eccleston Square, London, United Kingdom SW1V 1PX.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies.

The following principal accounting policies have been applied:

 
2.2

Going concern

The directors have placed a particular focus on the appropriateness of adopting the going concern basis in preparing the financial statements for the 17 month period ended 31 December 2024. Given the Company’s operating model, the directors believe that the Company has sufficient resources to meet its obligations as they fall due for the going concern assessment period to 31 May 2026. Based on this, together with available market information and the directors’ knowledge and experience of the Company, the directors continue to adopt the going concern basis in preparing the financial statements for the 17 month period ended 31 December 2024.

Page 3

 
AAVANTGARDE BIO UK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE 17 MONTH PERIOD ENDED 31 DECEMBER 2024

2.Accounting policies (continued)

 
2.3

Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Statement of Comprehensive Income within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.

  
2.4

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:
Revenue is recognised on a cost plus basis ranging from 6-12%, in line with the intercompany service agreement with the parent company. Intercompany revenue is recognised when all of the following conditions are satisfied :
- the amount of revenue can be measured reliably;
- it is probable that the Company will receive the consideration due under the intercompany service
agreement; and
- the costs incurred under the intercompany service agreement can be measured reliably.

 
2.5

Operating leases: the Company as lessee

Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term.

Page 4

 
AAVANTGARDE BIO UK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE 17 MONTH PERIOD ENDED 31 DECEMBER 2024

2.Accounting policies (continued)

 
2.6

Research and development

In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight-line basis over their useful economic lives, which range from 3 to 6 years.
If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.

 
2.7

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Statement of Financial Position. The assets of the plan are held separately from the Company in independently administered funds.

 
2.8

Current and deferred taxation

The tax expense for the 17 month period comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the Statement of Financial Position date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.

Page 5

 
AAVANTGARDE BIO UK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE 17 MONTH PERIOD ENDED 31 DECEMBER 2024

2.Accounting policies (continued)

 
2.9

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Computer equipment
-
Over 4 years

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

  
2.10

Trade and other receivables

Trade and other receivables are recognised initially at fair value, subsequently at amortised cost and, where relevant, adjusted for the time value of money. The Company assesses on a forward-looking basis, the expected recoverability associated with its trade receivables. If collection is expected in more than one year, the balance is presented within non-current assets.
In determining the expected recoverablility, the Company takes into account any recent payment behaviours and future expectations of likely default events (i.e. not making payment on the due date) based on individual customer credit ratings, actual or expected insolvency filings or company voluntary arrangements, likely deferrals of payments due and market expectations and trends in the wider macro-economic environment in which our customers operate.
Trade and other receivables are written off once all avenues to recover the balances are exhausted. Receivables written off are no longer subject to any enforcement activity

  
2.11

Cash and cash equivalents

Cash and cash equivalents comprise cash balances, deposits held at call with banks and other short-term highly liquid investments with original maturities of three months or fewer.

  
2.12

Trade and other payables

Trade and other payables with no stated interest rate and payable within one year are recorded at transaction price. Trade and other payables after one year are discounted based on the amortised cost method using the effective interest rate.

  
2.13

Expenses

Expenditure is expensed during the 17 month period.

Page 6

 
AAVANTGARDE BIO UK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE 17 MONTH PERIOD ENDED 31 DECEMBER 2024

2.Accounting policies (continued)

  
2.14

Share capital

Ordinary shares are classified as equity.

  
2.15

Intercompany loans

Amounts owed to Group undertakings
Amounts owed to Group undertakings are recognised initially at fair value less attributable transaction costs. Subsequent to initial recognition, amounts owed to Group undertakings are stated at amortised cost with any difference between the amount initially recognised and redemption value being recognised in the Statement of Comprehensive Income over the period of the loan, using the effective interest method.
Amounts due from Group undertakings
Amounts due from Group undertakings are recognised initially at fair value less attributable transaction costs. Subsequent to initial recognition, amounts due from Group undertakings are stated at amortised cost and, where relevant, adjusted for the time value of money. The Company assesses on a forward-looking basis, the recoverability losses associated with its amounts due from Group undertakings. A provision for impairment is made for the lifetime expected recoverability on initial recognition of the amounts due. If collection is expected in more than one year, the balance is presented within non-current assets.
In determining the expected recoverability, the Company takes into account any future expectations
of likely default events based on the level of capitalisation of the counterparty, which is a fellow
subsidiary undertaking of Aavantgarde Bio Srl.
 

  
2.16

Taxation

Income tax on the profit or loss for the year comprises current and deferred tax. Current tax is the tax payable on the taxable income for the year and any adjustment in respect of previous years. Deferred tax is provided in full using the Balance Sheet liability method on temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is determined using tax rates that have been enacted or substantively enacted by the reporting date and are expected to apply when the asset is realised, or the liability is settled.
No provision is made for temporary differences (i) arising on the initial recognition of assets or liabilities, other than on a business combination, that affect neither accounting nor taxable profit and (ii) relating to investments in subsidiaries to the extent that they will not reverse in the foreseeable future.

 
2.17

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

Page 7

 
AAVANTGARDE BIO UK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE 17 MONTH PERIOD ENDED 31 DECEMBER 2024

2.Accounting policies (continued)

 
2.18

Provisions for liabilities

Provisions are made where an event has taken place that gives the Company a legal or constructive obligation that probably requires settlement by a transfer of economic benefit, and a reliable estimate can be made of the amount of the obligation.
Provisions are charged as an expense to profit or loss in the year that the Company becomes aware of the obligation, and are measured at the best estimate at the Statement of Financial Position date of the expenditure required to settle the obligation, taking into account relevant risks and uncertainties.
When payments are eventually made, they are charged to the provision carried in the Statement of Financial Position.


3.


Employees

The average monthly number of employees, including the Director, during the 17 month period was as follows:


        2024
            No.






Average number of employees
17


4.


Tangible fixed assets





Computer equipment

£



Cost or valuation


Additions
58,425



At 31 December 2024

58,425



Depreciation


Charge for the 17 month period on owned assets
6,967



At 31 December 2024

6,967



Net book value



At 31 December 2024
51,458

Page 8

 
AAVANTGARDE BIO UK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE 17 MONTH PERIOD ENDED 31 DECEMBER 2024

5.


Trade and other receivables

2024
£


Amounts owed by group undertakings
3,220,442

Other debtors
93,654

Prepayments and accrued income
88,761

VAT recoverable
720,491

4,123,348



6.


Cash and cash equivalents

2024
£

Cash at bank and in hand
236,635

236,635



7.


Trade and other payables

2024
£

Trade creditors
1,477,099

Amounts owed to group undertakings
210,575

Corporation tax
95,166

Other taxation and social security
172,690

Other creditors
24,529

Accruals and deferred income
2,125,663

4,105,722


The unsecured amounts owed to Group undertakings are interest free, unsecured, repayable on
demand and with no fixed repayment date.

Page 9

 
AAVANTGARDE BIO UK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE 17 MONTH PERIOD ENDED 31 DECEMBER 2024

8.


Deferred taxation



2024


£






Charged to profit or loss
(6,732)



At end of year
(6,732)

The deferred taxation balance is made up as follows:

2024
£


Fixed asset temporary timing differences
(6,732)

(6,732)


9.


Share capital

2024
£
Authorised, allotted, called up and fully paid


1 ordinary share of £0.01
-



10.


Controlling party

The immediate parent company is Aavantgarde Bio Srl. 
The ultimate controlling party at 31 December 2024 was Aavantgarde Bio Srl, incorporated in Italy and registered at Via Visconti di Modrone, 18 20122 Milan Italy

 
Page 10